



# Who's Who at ESO 2025

---

Forty-Three Years  
of Education in Cancer Care  
1982-2025



European School  
of Oncology

[www.eso.net](http://www.eso.net)



## OUR VISION

To ensure that all cancer patients have access to unbiased and evidence-based competent care from adequately trained health professionals.

## OUR MISSION

The European School of Oncology is an independently funded non-profit organisation dedicated to quality education and training, because we believe all patients deserve equal access to competent cancer care.

## EDUCATIONAL PATHWAY


ESO offers medical, radiation and surgical oncologists a structured educational pathway that spans their career from medical students through to taking on leadership responsibilities.



# A STORY OF VISION AND GENEROSITY

**Umberto Veronesi**

Founder



The European School of Oncology was originally founded in 1982 by Umberto Veronesi, an Italian breast surgeon, visionary in cancer care and treatment and Princess Laudomia Del Drago, a distinguished member of the Roman aristocracy and a breast cancer survivor.

Both were passionate about reducing the number of cancer deaths as a result of late diagnosis or inadequate treatment. They believed that through increasing access to oncology education, cancer could not just be diagnosed sooner but treatment could improve, and in turn reduce the number of deaths.

Leading oncologists from around the world joined their cause, playing a key role in the founding of ESO. They include Sir Michael Peckham, Franco Cavalli, Louis Denis, and Bob Pinedo.

43 years on, we are continuing their initial passion by providing oncology education that helps improve the treatment of cancer patients. Through our extensive learning programmes, we're reaching areas where education is most needed, both geographically and scientifically.

## CO-FOUNDERS



**Michael Peckham**



**Louis Denis**



**Franco Cavalli**



**Bob Pinedo**



**Laudomia Del Drago**

Honorary President





# THE BOARD OF DIRECTORS

**Fedele Gubitosi**  
ESO President

**Members**

- Marco Alloisio *Milan*
- Alberto Azario *Milan*
- Piergiuseppe Biandrino *Milan*
- Donella Bossi Pucci *Rome*
- Roberto Camilli *Milan*
- Alberto Costa *Milan*
- Paola Favati *Milan*

- Vincenzo Finizzola *Milan*
- Thomas Galdy *Florence*
- Laura Pellegrini *Rome*

**Auditors**

- Marco B. Lovati *Milan (Chairman)*
- Barbara Negri *Milan*
- Stefano Sarubbi *Milan*

## ESO OFFICES



**Milan**  
Via Turati 29, 20121 Milano, Italy



**Bellinzona**  
Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland



## OUR FINANCIAL INDEPENDENCE

**Ugo Rock**

ESO Honorary President



Umberto Veronesi and Princess Laudomia Del Drago's vision of a School of Oncology inspired by European medical knowledge and tradition was sustained by the generosity of several private donors like Mr Jost Reinhold and Mr Hans Wyder in Milan. The turning point came through the support of the Necchi Campiglio family. Mr Necchi Campiglio was an Italian entrepreneur without children or heirs, whose metastatic prostate cancer was misdiagnosed as arthritis. The family decided that the sole heir of their patrimony would be ESO, guaranteeing its permanent financial stability and unique scientific independence.

This independence has given ESO the great privilege of being able to think freely and act freely in a world full of constraints and boundaries; a defining characteristic of ESO.

ESO's activities continue to be exclusively supported by private donations, which was Veronesi's initial dream.



Villa Necchi Campiglio in Milan, Italy.



## THE FFO FOUNDATION

---

**Antonello Perricone**

FFO President

The Fondazione per la Formazione Oncologica (FFO) was established in 1986 thanks to the effort of Professor Umberto Veronesi and the generous support made available by private donors to ensure financial stability to ESO.

The main purpose of the FFO, whose headquarters are in Milan, is the financial sustainability of ESO's activities. The Foundation, as well as the School, was conceived after a dramatic finding - according to the American Medical Association, up to an estimated 20% of all cancer deaths result from incorrect or delayed diagnosis or inadequate treatment. In other words, one in five people could be saved simply by applying knowledge and resources.

The Foundation is recognized as a public utility by the Lombardy Region and donations to it are tax deductible.

### FFO Board of Trustees:

**Antonello Perricone** *Milan*

**Michelangelo Balmelli** *Lugano*

**Andrea Cavallari** *Rome*

**Alberto Costa** *Milan*

**Fedele Gubitosi** *Milan*

**Laura Pellegrini** *Rome*

**Pietro Presti** *Turin*

**Giancarlo Pruneri** *Milan*

**Ugo Rock** *Milan*

**Gualtiero Ventura** *Milan*

### Auditors:

**Antonio Ortolani** *Milan*

**Uberto Barigozzi** *Milan*

**Giuseppe Munafò** *Milan*



# THE ESO FOUNDATION

**Carlo Maggini**  
ESOF President



The ESO Foundation was established in 1988 thanks to the legacies of Mrs. Gigina and Nedda Necchi to support and implement the project conceived in 1982 by Professor Umberto Veronesi and Princess Laudomia Del Drago. The Foundation's mandate is to secure resources that enable the School to develop initiatives that increase the skills of health professionals in the field of oncology, to support training projects and to accelerate the transfer of scientific advances to clinical practice.

ESOF is based in Lugano and is governed by a Board of Trustees.

ESOF and FFO annually assess ESO's activities and initiatives, support their implementation and monitor their effectiveness.

## ESOF Board of Trustees:

**Carlo Maggini** *Bellinzona*  
**Michelangelo Balmelli** *Lugano*  
**Fabrizio Barazzoni** *Lugano*  
**Franco Cavalli** *Bellinzona*  
**Maria Cristina Cedrini** *Lugano*  
**Alberto Costa** *Milan*  
**Fedele Gubitosi** *Milan*  
**Carlo Marazza** *Locarno*  
**Glauco Martinetti** *Bellinzona*  
**Laura Sadis** *Lugano*  
**Alessandro Rusconi** *Lugano*  
**Lorenza Wyder** *Munich*







## 2023-2025 **STRATEGIC PLAN**

The European School of Oncology Strategic Plan aims to define the new strategy in the triennium 2023-25.

### **GOVERNANCE**

ESO is a non-profit educational organisation, which has no membership and does not hold elections for its governance committees. The Organization chart is available on page 9.

### **ESO's MAIN EDUCATIONAL ACTIVITIES**

- Postgraduate programmes (see pages 18-20)
- Masterclasses
- e-Learning (see page 16)
- Clinical TrainingCentres (CTC) Fellowships
- Visiting Professorship Programmes
- Refresher Courses
- Medical Students Courses in Oncology

### **COLLEGE**

The College of the European School of Oncology offers aspiring medical, radiation and surgical oncologists a structured educational pathway that spans their career from medical student through to taking on leadership responsibilities (see page 14).


### **STRATEGIC OBJECTIVES**

- Adapt the investment in distance learning (e-learning, e-ESO) by increasing quality instead of quantity
- Improving the “Clinical Training Centers” programme by increasing the host centres and strengthening the network
- Strengthen ESCO activities by creating the basics for a new generation of oncologists trained through a merit-based structured path
- Consolidate collaboration with European universities to provide recognized educational credits (ECTS) in the context of the prevalent oncological diseases and topics
- Increase collaboration with ECO (European Cancer Organization) by contributing to the EU's Beating Cancer Plan
- Cancer disparities programme: overcoming the East / West divide by directing educational activity where it is needed
- Implement practical intervention models on the ground in specific countries with measurable results
- Introduce elements of artificial intelligence in teaching to increase the number of languages available
- Improve practical training for surgical oncologists through artificial models and simulators
- Create a platform that contains the main achievements of European oncology: the ONCOpedia project
- Find strategic alliances with foundations that have complementary or similar institutional missions



# ORGANIZATION CHART

As of October 2024





# MANAGING ESO

**Alberto Costa**  
Chief Executive Officer

Dr Alberto Costa, a breast cancer surgeon from Milan with previous research activity in the field of cancer chemoprevention, was appointed ESO’s Director in 1982. He took on the task of establishing the School, its offices and its first activities and has managed ESO ever since.

For over 30 years, Dr Costa single handedly designed ESO’s annual programme of activities whilst reporting to the Board of Directors and the Scientific Committee. In 2017 the Board confirmed his position as CEO. He is responsible for the scientific content of ESO’s activities.

He was editor in chief of the journal *The Breast* from 2003 to 2015 and a member of the editorial board of *Nature Reviews Clinical Oncology*. He has also been the Editor, from 2015 to 2019, of the ESO magazine, *CancerWorld*.

Co-founder of ABC, Advanced Breast Cancer conference, Europa Donna, the European Breast Cancer Coalition, he also founded Europa Uomo, the patient advocacy movement on prostate cancer. He has served as Secretary General of the European Organisation for the Research and Treatment of Cancer (EORTC) and the Federation of European Cancer Societies (FECS), both in Brussels. He actively contributed to the establishment and development of the American Italian Cancer Foundation (AICF) in New York, of which is member of the Advisory Board.

From 2021-2024, he served as adviser of the EU Commissioner for Health, Mrs Stella Kyriakides, for cancer policy.



Villa Verganti Veronesi, ESO premises  
in the countryside near Milan



## MANAGING ESO

### Rossella Blasi

Executive Director



From January 2023 Mrs Rossella Blasi, senior manager in human resources and finances, joined the CEO office, with the task of coordinating the Milan and Bellinzona offices and to support the CEO in his multiple activities.

Rossella Blasi has over 20 years of experience in the charity in the management and coordination of non-profit organisations, with a particular focus on Human and Financial Resources.

She joined ESO with the role of Director of the CEO Office, supporting the CEO in coordinating the offices located in Milan, Italy and Bellinzona, Switzerland.

Later on, she was appointed the position of Executive Director to encourage the growth of the School in its mission of promoting oncology training, implementing strategies aimed at improving processes and bringing attention to the context and the concreteness of the results in each project.

Rossella has contributed to the internal reorganisation of the activities, reviewing some of the agreements signed with our main partners. She has also began the corporate restructuring of internal skills with a view to strengthening the services offered by the School and reopening the traditional Venetian venue of San Servolo island.

One of the best known ESO locations, which it used for many years, was a former Benedictine monastery on the island of San Servolo in Venice. In recent times it had been home to a psychiatric hospital, but when that closed due to the reorganisation of Italy's psychiatric services, ESO was offered the use of its premises. For many people this is the site most closely associated with ESO.





# MULTIDISCIPLINARY SCIENTIFIC COUNCIL

The Multidisciplinary Scientific Council (MSC) is a group of highly experienced professionals, carefully selected by ESO, tasked with providing transparent monitoring and evaluation of the scientific content of the School's activities. The MSC not only reviews and approves teaching subjects and speakers based on their expertise, but also ensures balanced representation in terms of gender, geographic diversity, and multidisciplinary perspectives.

This approach guarantees that our programmes not only meet the highest scientific standards but also reflect a broad, inclusive, and European perspective.



## Alessandra Curioni Fontecedro

**MEDICAL  
ONCOLOGY**

Prof. Alessandra Curioni Fontecedro was appointed Full Professor of Oncology at the University of Fribourg in 2022 and works as Head of Oncology at the Cantonal Hospital HFR Fribourg, Switzerland. She is Vice-President of the Immuno-Oncology Group of the Swiss Group for Clinical Cancer Research (SAKK), as well as a faculty member of the Immuno-Oncology and Immunotherapy Group at ESMO.



## Nicola Fusco

**PATHOLOGY**

Prof. Nicola Fusco is the Director of the Division of Pathology at the European Institute of Oncology (IEO) and Associate Professor of Pathological Anatomy at the Department of Oncology and Haemato-Oncology of the University of Milan. In addition, he directs the institutional Biobank at the IEO and actively participates in an international network of experts in predictive oncological pathology.



## Barbara Jereczek Fossa

**RADIATION  
ONCOLOGY**

Prof. Barbara Jereczek Fossa is a Full Professor of Radiation Oncology at the University of Milan and Chair of the Radiation Oncology Department at the European Institute of Oncology (IEO), Milan, Italy. She is President Elect of the European Society of Radiotherapy and Oncology (ESTRO) and actively contributes to various scientific societies, committees, and editorial boards,



## Riccardo Audisio

**SURGICAL  
ONCOLOGY**

Prof. Riccardo Audisio is Professor at the Institute of Clinical Sciences, University of Göteborg, Sweden and is Editor-in-Chief of the European Journal of Surgical Oncology (EJCO). He is Past-President of the European Society of Surgical Oncology (ESSO) and member of several international scientific societies including BASO, SSO, AAA, SIOG and EUSOMA.

# THE ADVISORY BOARD


## Nicholas Pavlidis



After many years ESO decided to replace the Scientific Committee with an Advisory Board including representatives of the civil society, universities and experts in communication, artificial intelligence (AI) and health economics.

Prof. Nicholas Pavlidis served as Senior Oncologist at the Cancer Institute in Athens before moving to the University of Ioannina where he was elected as Professor of Medical Oncology and held the position of Head of the Department of Medical Oncology at Ioannina University Hospital from 1988 to 2016.

Since 1989, Prof. Pavlidis has served the European School of Oncology as the Chair of Eastern European and Balkan activities, member of the Scientific Committee, Masterclass Coordinator and he is currently the Chair of the Advisory Board. Among his research activities, cancer of unknown primary and cancer during pregnancy were the two topics where he mainly dedicated his scientific interest for many years.



## CO-CHAIR

## Stella Kyriakides

Stella Kyriakides is a prominent Cypriot politician and health advocate who served as the European Commissioner for Health and Food Safety from December 2019 to November 2024. Prior to this role, she was a member of the Cyprus House of Representatives from 2006 to 2019. In 2017, she made history by becoming the first Cypriot and the fourth woman to be President of the Parliamentary Assembly of the Council of Europe.

Kyriakides has held several leadership positions, including President of the Human Rights Committee and Vice President of the Health Committee in the Cyprus Parliament. She also chaired the Health and Social Affairs Committee of the Parliamentary Assembly and led the European Breast Cancer Coalition Europa Donna. A strong advocate for patient rights, Kyriakides founded Europa Donna, Cyprus' first breast cancer association, and served as its president for 15 years. She also worked in the Cyprus Mental Health services as a psychologist, focusing on child and adolescent mental health. For her significant contributions to the field of health, Stella Kyriakides was awarded an honorary Doctor of Science degree from the University of Reading.

### Chair

**Nicholas Pavlidis** Ioannina

### Co-Chair

**Stella Kyriakides** Cyprus

### Members

**Marta Bertolaso** Rome

**Filippo De Braud** Milan

**Lesley Fallowfield** Brighton

**Luca Gambardella** Lugano

**Mark Lawler** Belfast

**Simon Oberst** Cambridge

**Salah Dine Qanadli** Rennaz

**Luzia Travado** Lisbon

**Eric Van Cutsem** Leuven

### Members ex officio

**Matti Aapro** Geneva (SPCC)

**Franco Cavalli** Bellinzona (ESOF)

**Christian Rolfo** New York (CROH)

**Virpi Sulosaari** Kaarina (EONS)





# DOMIETTA DEL DRAGO FELLOWSHIP FUND

Donella Bossi Pucci

The two principle founders of the European School of Oncology were Professor Umberto Veronesi, the visionary surgeon who had just published his seminal paper on conservative surgery for breast cancer in the New England Journal of Medicine, and Princess Laudomia (Domietta) Del Drago, distinguished member of the Roman aristocracy and a breast cancer survivor. Veronesi had the original idea of a school of oncology for Europeans inspired by European medical knowledge and tradition. He became the first chair of the School's Scientific Committee, which initially included the Swiss medical oncologist and haematologist Franco Cavalli, the Belgian urologist Louis Denis, the British radiotherapist Michael Peckham and the Dutch medical oncologist Bob Pinedo.

Del Drago gave the School its first donation (first of a long series!) and became President of the School's Board of Directors. She continued to support ESO throughout her life and when she passed away in 2019 she asked her daughter, Donella, to ensure their family continued its financial commitment to the European School of Oncology, together with our private European donors.

The Domietta Del Drago fellowship fund was established in January 2020 in her memory and has the scope of providing financial aid to doctors and nurses who have successfully passed the selection process for one of ESO's educational programmes, but have difficulties in covering their participation costs.





# THE COLLEGE OF THE EUROPEAN SCHOOL OF ONCOLOGY

## MISSION

The College of the European School of Oncology offers a structured educational pathway for ESO students to follow and enhance their oncology careers.

Eso College ([www.esco.org](http://www.esco.org)) was launched in July 2020 and offers aspiring medical, radiation and surgical oncologists a structured educational pathway that spans their career from medical student through to taking on leadership responsibilities.

The educational pathway is structured in levels, in accordance with career development targets. When each level is achieved, members are able to access dedicated benefits that are targeted to help them reach the following level and eventually graduate. These benefits include: Subscription to ScienceDirect, Discount registration fees at selected oncology events and examinations, Access to members only e-learning Sessions, Priority selection for ESO Clinical Training Centres Fellowship Programme, Scholarships for ESO Postgraduate programmes, Career advice via a virtual Mentorship programme, Dedicated improving outcomes and leadership course, Grants for further education, Access & participation in the College Directory and Library.

Only doctors who have already been selected to participate in one of ESO's competitive activities can join the College.

## CHAIRMAN

**Alexandru Eniu**



Dr Alexandru Eniu is the Chairman and entrusted with the task of developing the college. He is currently senior medical oncologist at Hôpital Riviera-Chablais, in Rennaz, Switzerland after working for many years at the Cancer Institute Ion Chiricuta in Cluj-Napoca, Romania. He is an internationally recognized breast cancer expert, with a prestigious publication track and also has a keen interest in public health and access to oncological care.

In 2024, a College Council will be established, consisting of eight members who will be nominated and elected by the College membership. The Council's primary role will be to shape and advance the College's growth, while also expanding career development opportunities within the School.



## ESO e-LEARNING

---

ESO e-Learning ([www.e-ESO.net](http://www.e-ESO.net)) is a free e-learning platform that has been providing educational opportunities and resources for oncology professionals for 16 years. Committed to keeping pace with technological advancements, ESO aims to make online education accessible to everyone, regardless of their location. As part of this ongoing commitment, the platform is evolving significantly.

Starting in 2025, a revamped ESO website will incorporate the e-ESO platform, offering a more organized and user-friendly experience for navigating educational materials.

A new e-learning platform will be developed to host online courses, materials for the Certificate of Competence, EU project resources, and pre-recorded materials useful for in-person events. However, regular weekly sessions will no longer be offered. This strategic shift reflects ESO's dedication to providing comprehensive and accessible educational opportunities in oncology.

### ESO e-Learning resources are:

- without any commercial sponsorship
- interactive – participants can send questions to the expert
- on-demand so participants can view in their own time and pace








# ONCOpedia

EUROPEAN HISTORY OF ONCOLOGY

## Silvio Monfardini

Chair



The European ONCOpedia ([www.oncopedia.wiki](http://www.oncopedia.wiki)) is a European School of Oncology project to document the history of Europe's contributions to improving cancer care. It aims to give insights into how those contributions came about, and what difference they made to patients, by hearing where possible, directly from the people who were involved.

The European School of Oncology chose to focus the ONCOpedia on European contributions, because this is our core community and we want to tell our own story. However, we are also keen to acknowledge instances where the contributions covered include important input from the US or elsewhere.

### Editorial Committee:

**Chair:** Silvio Monfardini

**Editorial Director:** Bernardino Fantini

**Co-chairs:** Alberto Costa, Nicholas Pavlidis

**Editorial coordinator:** Anna Wagstaff

### Committee members:

Adriana Albini, Riccardo Audisio, Mariano Barbacid, Alessandro Blasimme, Giovanni Boniolo, Bettina Borisch, Alberto Cambrosio, Steven Pavletic, Philip Poortmans, Paolo Vineis and Theo Wagener



## THE ESO OFFICIAL JOURNAL

**Christian Rolfo**



The School's official journal is *Critical Reviews in Oncology/Hematology* (CROH), whose editor-in chief is Dr. Christian Rolfo (New York). CROH publishes scholarly, critical reviews in all fields of oncology and hematology, as well as reviews and original research articles in the field of geriatric oncology. The journal also facilitates the diffusion of ESO articles.



# COORDINATORS OF THE POSTGRADUATE PROGRAMMES



## BREAST CANCER

---

**Matteo Lambertini**

From the very beginning, ESO has devoted special attention to breast cancer, the most common cancer in women worldwide. Our founder Umberto Veronesi dedicated much of his career towards breast cancer research and it is also the specialty research field of our CEO, Alberto Costa.

The **Certificate of Competence in Breast Cancer (CCB)** was launched in 2015 and is the first competence programme to focus on the improvement of both the clinical and the scientific capability of oncologists, ensuring better-quality management of breast cancer patients.  
The CCB programme is held in collaboration with Ulm University, Ulm, Germany.



## GASTROINTESTINAL CANCERS

---

**Sara De Dosso**

Gastrointestinal cancers represent almost 1/4 of all cancers diagnosed in adults and include colorectal cancer, stomach cancer, pancreatic cancer and liver cancer.

The **Certificate of Advanced Studies in Gastrointestinal Cancer (CAS-GI)** is the first competence programme to focus on the improvement of both the clinical and scientific capability of oncologists, ensuring better-quality management of patients with gastrointestinal cancers.  
The CAS-GI programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland. The second cohort started in June 2024 and will end in November 2025.

## GYNAECOLOGICAL CANCERS

---

**Cristiana Sessa**



The first edition of the **Certificate of Advanced Studies in Gynaecological Cancers (CAS-Gyn)** was launched in 2023 and is the first competence programme to focus on advancing the knowledge and science in the management of patients affected by gynaecological cancers.

The CAS-Gyn programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland.

The first cohort started in August 2023 and ended in January 2025.

The second cohort will begin in June 2025 and will end in late 2026.

## LYMPHOMA

---

**Emanuele Zucca**



Lymphomas are also a high priority field for ESO as Prof. Franco Cavalli, a key authority in the field, has been involved in ESO activities from the very beginning.

The **Certificate of Competence in Lymphoma (CCL)** was launched in 2013 and is the first competence programme to focus on the improvement of both the clinical and the scientific capability of oncologists, ensuring better-quality management of lymphoma patients.

The CASLYM programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland. The next cohort will start in June 2025 and will conclude in early 2027.



# PROSTATE CANCER

---

**Ursula Vogl**

The decision to prioritize prostate cancer research was taken to honor the memory of a major donor to the School who passed away due to the disease. This choice also acknowledges the need to focus on relatively under-researched areas within prostate cancer care: active surveillance and the study of predictive and prognostic factors.

The **Certificate of Advanced Studies in Prostate Cancer (CAS-Pr)** is a postgraduate programme focused on the improvement of both the clinical and scientific capability of oncologists, aiming to ensure better-quality management of patients with prostate cancer. The CAS-Pr programme is held in collaboration with the Università della Svizzera italiana (USI), Lugano, Switzerland.

The second cohort will start in September 2025 and will end in late 2026.



# THORACIC MALIGNANCIES

---

**Alessandra Curioni Fontecedro**

The **Certificate of Advanced Studies in Thoracic Malignancies (CAS-TM)** was launched in 2025 and the programme will focus on the improvement on both the clinical and the scientific aspects of improving quality in the management of patients with lung cancer and other thoracic malignancies.

The CAS-TM programme is held in collaboration with the University of Fribourg, Switzerland. The first cohort started in March 2025 and will end in June 2026.

Alessandra Curioni Fontecedro, who previously served as Deputy Director Lung and Thorax Cancer Centre at the University Hospital Zurich, was appointed Full Professor of Oncology at the University of Fribourg and Director of Oncology at the Hospital of Fribourg, Switzerland in 2022 and serves as the ESO Advisor and Chair of the CAS-TM programme.





## EU PROJECTS

ESO is involved in different European Projects either alone or with other oncology stakeholders. Here is a brief summary of the main ongoing activities and future plans.

### INTERACT EUROPE

Programme: EU4Health

<https://www.europeancancer.org/eu-projects/impact/interact-europe>



INTERACT-EUROPE is an 18-month project (July 2022 - November 2023) co-funded by the EU under the EU4Health programme 2021-2027 as part of Europe's Beating Cancer Plan. INTERACT-EUROPE brought together 33 partners from 17 countries aiming at developing a European inter-specialty cancer training programme involving all main oncology disciplines and professions, cancer centres and patient groups, based on relevant needs assessments. The project was coordinated by ECO and ESO was involved in WP3 and in WP4 providing both online and in person education.

### COMPREHENSIVE CANCER INFRASTRUCTURE FOR THE EUROPEAN UNION (CCI4EU)

Programme: EU4Health

<https://www.europeancancer.org/eu-projects/impact/interact-europe>



CCI4EU is a coordination and support action (CSA) geared towards supporting Member States and Associated countries in developing or improving existing or future Comprehensive Cancer Infrastructures (CCI) by fostering research innovation and digital capacity development in cancer care. A tailored Capacity Building programme has been devised to fulfil the aim of this action: ensuring that 90% of cancer patients are treated in Comprehensive Cancer Infrastructures by 2030.

The project is coordinated by OEI and involves 27 beneficiaries, 28 affiliated entities and 2 third parties. ESO is involved in all WPs but is the leader of WP5 (providing online education and coordinating other partners in their assigned activities) and has some specific tasks in WP6 (the organisation of 3 regional Capacity Building Conferences). The project lasts 3 years (May 2023 – April 2026).

### INTERACT-EUROPE 100

Programme: EU4Health



The INTERACT-EUROPE 100 project aims at implementing the Inter-specialty Cancer Training (ISCT) curriculum developed under the INTERACT-EUROPE project. The objective of the ISCT programme is to foster a patient-centric approach to quality cancer care through the promotion of multidisciplinary and multi-professional teams working across Europe.

The project is co-funded by the EU under the EU4Health programme 2021-2027 as part of Europe's Beating Cancer Plan, it is coordinated by ECO and ESO is the leader of Work Package 3 on the delivery of the ISCT programme by overseeing the training of trainers (experts in the fields of clinical oncology, surgery, radiation oncology, cancer nursing and other specialised staff from at least 100 cancer centres in Europe) and subsequently that of trainees.

INTERACT2 is a 36-month project (December 2023 – November 2026).

### ERASMUS+

Furthermore, ESO has applied/is applying to some ERASMUS+ grants and has recently been assigned a mobility fund to cover 24 fellowships in 2025.





# ESO BOUNDARIES: A SPECIFIC MISSION

ESO’s teaching activities are held predominately in Europe but access to them is European in a broad sense, this includes non EU countries, areas going East until Eurasia, and those areas which have a close link with European culture and languages, like the Mediterranean area and Central and Latin America.





2025  
**ESO TEAM**



**Rossella Blasi**  
Executive Director



**Alessandra Antenucci**  
Accounting



**Sonia Bulgarelli**  
Event Manager



**Alice Ciocchini**  
Event Manager



**Mariachiara Deleo**  
Communication Coordinator



**Elena Fiore**  
Event Manager



**Corinne Hall**  
ESO College Manager



**Dolores Knupfer**  
Event Manager



**Gabriele Maggini**  
Bellinzona Office Manager  
and ONCOpedia



**Francesca Marangoni**  
Grant Office Coordinator



**Sarah Jane Ortelli Giannakis**  
Event Manager



**Alexandra Zampetti**  
Event Manager

**COLLABORATORS**



**Fausta Amati**  
Administration



**Sarah Goldman**  
External Consultant



**Michele Guerrieri**  
Legal Adviser



**Lorenzo Pini**  
IT Manager



## CONTACT US

### MILAN OFFICE

Via Turati 29  
20121 Milano,  
Italia

### BELLINZONA OFFICE

Via Vincenzo Vela 6  
6500 Bellinzona,  
Switzerland

   @ESOncology

 European School of Oncology

eso@eso.net

**www.eso.net**